Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment (CaboLife)
CaboLife: A Prospective Non-Interventional Study on Effectiveness and Safety of Cabozantinib in Real-Life Setting for Previously Treated Patients With Neuroendocrine Tumour
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ipsen Clinical Study Enquiries
- Phone Number: See e mail
- Email: clinical.trials@ipsen.com
Study Locations
-
-
-
Graz, Austria
- Recruiting
- Medizinische Universitaet Graz
-
Linz, Austria
- Not yet recruiting
- Kepler Universitaetsklinikum GmbH Linz
-
Vienna, Austria
- Recruiting
- Medizinische Universität Wien
-
-
-
-
-
Aschaffenburg, Germany
- Recruiting
- MVZ am Klinikum Aschaffenburg
-
Berlin, Germany
- Recruiting
- Evangelische Lungenklinik Berlin
-
Berlin, Germany
- Recruiting
- DRK Kliniken Berlin
-
Berlin, Germany
- Recruiting
- Charité - Universitaetsmedizin Berlin
-
Bonn, Germany
- Not yet recruiting
- Johanniter-Kliniken Bonn
-
Bremen, Germany
- Recruiting
- Krankenhaus St. Joseph-Stift Bremen GmbH
-
Chemnitz, Germany
- Not yet recruiting
- Klinikum Chemnitz
-
Cologne, Germany
- Recruiting
- pioh Studien und Mangement GbR
-
Cologne, Germany
- Recruiting
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
-
Dresden, Germany
- Recruiting
- Gemeinschaftspraxis Haematologie - Onkologie
-
Dresden, Germany
- Recruiting
- Technische Univiersitaet (TU) Dresden
-
Erlangen, Germany
- Recruiting
- Universitaetsklinikum Erlangen
-
Essen, Germany
- Recruiting
- Universitaetsklinikum Essen
-
Frankfurt, Germany
- Not yet recruiting
- Krankenhaus Nordwest
-
Frankfurt am Main, Germany
- Not yet recruiting
- Uniklinikum Frankfurt
-
Freiburg im Breisgau, Germany
- Recruiting
- Universitaetsklinikum Freiburg
-
Giesen, Germany
- Not yet recruiting
- Universitaetsklinikum Giessen-Marburg
-
Goettigen, Germany
- Recruiting
- Universitaetsmedizin Goettingen
-
Hamburg, Germany
- Recruiting
- Universitaetsklinikum Hamburg-Eppendorf
-
Hamburg, Germany
- Not yet recruiting
- Asklepios Kliniken Hamburg
-
Heidelberg, Germany
- Not yet recruiting
- Universitaetsklinikum Heidelberg
-
Kiel, Germany
- Not yet recruiting
- UKSH Kiel
-
Leer, Germany
- Not yet recruiting
- Studienzentrum UnterEms
-
Leipzig, Germany
- Not yet recruiting
- MVZ Leipzig Mitte, MVZ Delitzsch
-
Leipzig, Germany
- Not yet recruiting
- Universiteatsmedizin Leipzig
-
Ludwigsburg, Germany
- Recruiting
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH
-
Lübeck, Germany
- Not yet recruiting
- UKSH Luebeck
-
Mainz, Germany
- Not yet recruiting
- Universitaetsmedizin Mainz
-
Marburg, Germany
- Recruiting
- Philipps-Universitaet Marburg
-
Minden, Germany
- Recruiting
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
-
Mülheim, Germany
- Recruiting
- MVZ Muelheim an der Ruhr GmbH
-
München, Germany
- Not yet recruiting
- TUM Klinikum Muenchen
-
Münster, Germany
- Not yet recruiting
- Universitaetsklinikum Muenster
-
Osnabrück, Germany
- Not yet recruiting
- MVZ Onkologie Klinikum Osnabrueck GmbH
-
Saarbrücken, Germany
- Not yet recruiting
- Universitaestklinikum Saarbruecken
-
Tübingen, Germany
- Recruiting
- Universitätsklinikum Tuebingen
-
Westerstede, Germany
- Recruiting
- Medizinische Studiengesellschaft Nord-West
-
Würzburg, Germany
- Recruiting
- Universitaetsklinikum Wuerzburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.
Description
Inclusion Criteria:
Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion Criteria:
Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease Control Rate (DCR)
Time Frame: At 6 Months
|
Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care. |
At 6 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: Up to 18 Months
|
Proportion of participants who achieve complete or partial response based on radiographic assessments. |
Up to 18 Months
|
|
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
Time Frame: Baseline and Every 3 Months up to 18 Months
|
A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). |
Baseline and Every 3 Months up to 18 Months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
Time Frame: Baseline and Every 3 Months up to 18 Months
|
A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning). |
Baseline and Every 3 Months up to 18 Months
|
|
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
Time Frame: Up to 18 Months
|
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention. |
Up to 18 Months
|
|
Percentage of participants with any dose modification due to AEs.
Time Frame: Up to 18 months
|
Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period. |
Up to 18 months
|
|
Duration of treatment (DoT)
Time Frame: Up to 18 Months
|
Time from first dose to last dose of cabozantinib. |
Up to 18 Months
|
|
Percentage of participants switching to a new line of therapy
Time Frame: Up to 18 Months
|
Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure. |
Up to 18 Months
|
|
Disease control rate after switch to next line of therapy
Time Frame: 3 Months After Therapy Switch
|
Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care. |
3 Months After Therapy Switch
|
|
Chromogranin A Levels
Time Frame: Baseline and Every 3 Months up to 18 Months
|
Chromogranin A blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Neuron-Specific Enolase blood levels.
Time Frame: Baseline and Every 3 Months up to 18 Months
|
Neuron-Specific Enolase blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Time to next treatment
Time Frame: Up to 18 Months
|
Time from first dose of cabozantinib to initiation of subsequent therapy. |
Up to 18 Months
|
|
Progression-Free Survival (PFS)
Time Frame: Up to 18 Months
|
Time from first dose of cabozantinib to disease progression or death from any cause. |
Up to 18 Months
|
|
Progression-Free Survival Rate at 12 and 18 Months
Time Frame: At 12 and 18 Months
|
Number of participants without disease progression or death. |
At 12 and 18 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Ipsen Medical Director, Ipsen
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CLIN-60000-467
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD Sharing Time Frame
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).
IPD Sharing Access Criteria
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.